ICON Appoints Dr. Neil McCullough as Executive Vice President of Quality and Compliance and Corporate Training
Dublin, Ireland, 28th May, 2013 – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Dr. Neil McCullough as Executive Vice President of Quality and Compliance and Corporate Training. In this role, Neil will provide strategic direction for quality management, quality assurance and corporate training across all ICON lines of business, ensuring ICON continues to deliver high quality solutions to clients that are fully compliant with the evolving global regulations guiding the biopharmaceutical industry.
Neil brings to ICON over 22 years of experience leading global quality functions for pharmaceutical and clinical research organisations. Prior to ICON, Neil led the global quality and compliance division of PPD, before which he spent nine years at Pfizer Inc. as a member of the Pfizer Global Medical Quality Assurance Leadership team. Prior to Pfizer, Neil served as a quality consultant to GlaxoSmithKline's division of manufacturing. Neil earned his doctorate in chemistry from the University of Kent at Canterbury in the UK and his masters in pharmaceutical medicine from Hibernia College, Dublin, in partnership with Harvard University and the Royal College of Physicians, Ireland.
Commenting on the appointment, Ciaran Murray, CEO ICON plc, said: "I would like to welcome Neil to ICON's executive leadership team. Delivering quality data and services to the standards required by clients and that are fully compliant with the evolving requirements of regulatory authorities underpins everything we do. Neil's leadership and industry expertise will allow us to further enhance the quality and compliance solutions we offer to clients in support of their global drug development programmes."
The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in Forms 20-F for the fiscal year ended December 31st 2012 and in the other forms filed with the US Securities and Exchange Commission, including the F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 10,200 employees, operating from 79 locations in 37 countries.